Session Abstract – PMWC 2022 Silicon Valley

 Session Chair Profile

Ph.D., Founder and CEO, Insilico Medicine, Inc

Biography
Alex Zhavoronkov, PhD, is the founder&CEO of Insilico Medicine, a leader in next-generation artificial intelligence technologies for drug discovery and biomarker development. He is also the founder of Deep Longevity, developing a broad range of artificial intelligence-based biomarkers of aging and longevity servicing healthcare providers and insurance industry. Since 2015 he has invented critical technologies in the field of GANs and reinforcement learning for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for the prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. He has published over 130 peer-reviewed research papers and 2 books. He serves on the editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, Frontiers in Genetics, and co-chairs the Annual Aging Research,Drug Discovery, and AI Forum.


 Speaker Profile

Ph.D., VP, Global Head In Silico Discovery & External Innovation, Janssen

Biography
Jim Edwards is currently leading a multi-disciplinary group of computational & data scientists providing predictive and design tools across all modalities within the Therapeutics Discovery organization at Janssen, starting at project inception through the identification of clinical candidates. Primary to this, Jim was US Regional Head, Discovery Chemistry at Janssen Research & Development, leading drug discovery teams in South Francisco & La Jolla CA, Boston, MA, and Spring House, PA. These teams were responsible for the design and synthesis of small molecule drug candidates working with partners across DPDS and all six Therapeutic Areas within JRD. From 1999-2014, Jim led various Immunology medicinal chemistry groups at Janssen which delivered clinical-stage molecules against multiple novel first-in-class targets. Jim received his Ph.D. from the University of Illinois, Urbana-Champaign, working with Professor Scott Denmark, and performed post-doctoral studies with Professor Lanny Liebeskind at Emory University.


 Speaker Profile

Ph.D., Chief Data Science Officer and Global Head, Janssen R&D Strategy and Operations, Johnson & Johnson

Biography
Najat Khan, PhD, is the Chief Data Science Officer and the Global Head of Strategy & Operations for Janssen Research & Development. In these roles Dr Khan leads a team of 100+ data scientists and data engineers to drive deep impact across Janssen’s pipeline and portfolio and shapes Janssen’s R&D strategy, spanning key pipeline and portfolio decisions to new strategic initiatives to deliver on transformational medicines for patients. Dr Khan co-chairs the Johnson & Johnson Data Science Council and is a member of Janssen’s Development and Investment Committees. Dr Khan was a Senior Principal at The Boston Consulting Group and received her Ph.D. in Organic Chemistry from the University of Pennsylvania and her B.A. in Chemistry with a minor in Economics from Colgate University.


 Speaker Profile

M.D., DPHIL, CEO, Arctoris Ltd

Biography
Martin-Immanuel Bittner is the CEO of Arctoris, the drug discovery platform company that he co-founded in Oxford in 2016. Martin graduated as a medical doctor from the University of Freiburg in Germany, followed by his DPhil in Oncology as a Rhodes scholar at the University of Oxford. He has extensive research experience covering both clinical trials and preclinical drug discovery and is an active member of several leading cancer research organisations, including EACR, AACR, and ESTRO. In recognition of his research achievements, he was elected a member of the Young Academy of the German National Academy of Sciences and of Sigma Xi.